Concepts of clot lysis.
Physiologic thrombolysis is efficient, while pathologic aberrations in the fibrinolytic system may result in either thrombotic or hemorrhagic disease. This review considers the molecular interactions involved in fibrinolysis, discusses the normal control mechanisms that provide for localized activation without systemic effects, and describes the molecular mechanism of plasmic degradation of fibrinogen and of cross-linked fibrin. The consequences of excessive or deficient fibrinolysis are discussed and specific examples cited of pathologic hemostasis directly related to abnormalities in the fibrinolytic system.
D000818:Animals; D001777:Blood Coagulation; D001778:Blood Coagulation Disorders / Q000097:blood / Q000209:etiology / Q000503:physiopathology; D004211:Disseminated Intravascular Coagulation / Q000097:blood / Q000209:etiology / Q000503:physiopathology; D004285:Dogs; D005337:Fibrin / Q000378:metabolism; D005338:Fibrin Fibrinogen Degradation Products; D005340:Fibrinogen / Q000037:antagonists & inhibitors; D005341:Fibrinolysin / Q000378:metabolism; D005342:Fibrinolysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006470:Hemorrhage / Q000097:blood / Q000378:metabolism / Q000503:physiopathology*; D006706:Homeostasis; D006801:Humans; D007049:Iatrogenic Disease; D010958:Plasminogen / Q000037:antagonists & inhibitors / Q000378:metabolism; D010960:Plasminogen Activators / Q000378:metabolism; D011817:Rabbits; D013300:Streptokinase / Q000627:therapeutic use; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use; D000979:alpha-2-Antiplasmin / Q000378:metabolism
D005338:Fibrin Fibrinogen Degradation Products; D005343:Fibrinolytic Agents; D000979:alpha-2-Antiplasmin; D005337:Fibrin; D005340:Fibrinogen; D010958:Plasminogen; D013300:Streptokinase; D010960:Plasminogen Activators; D005341:Fibrinolysin; D014568:Urokinase-Type Plasminogen Activator